Karyopharm is no longer a two-franchise oncology story. The residual common equity is a distressed call on whether selinexor plus ruxolitinib can become the first approved combination in myelofibrosis before the September term-loan installment and the minimum-liquidity covenant force a default, a deeply dilutive recap, or a sale run by Centerview Partners. The July miss in the endometrial maintenance study removed the second growth pillar that the capital structure had been stretching to reach. What remains is a mature United States myeloma franchise that still prints product revenue and a single late-stage hematology package that the Food and Drug Administration has already treated as eligible, in writing, for an accelerated path on spleen-volume reduction. The market is not arguing about whether XPOVIO still sells in community myeloma clinics. It is arguing about whether common still owns the myelofibrosis upside after the next payment date.
The SENTRY Phase Three readout in March is the load-bearing clinical event. Half of combination patients hit a thirty-five percent spleen-volume reduction at week twenty-four against roughly a quarter on ruxolitinib alone, and a later overall-survival cut showed a hazard ratio well below one half. The symptom co-primary did not separate, which is why the agency conversation shifted to whether spleen shrinkage is a reasonably likely surrogate for survival rather than a dual-endpoint win. Written FDA feedback that SVR35 appears to qualify as that surrogate is what lets management keep an August supplemental filing on the calendar after Type B and Type C meetings. That regulatory opening arrived in the same season as the XPORT-EC-042 miss, where a trend in progression-free survival in TP53 wild-type endometrial cancer failed to clear statistical significance and the company stopped new investment in the solid-tumor arm. The mechanism is simple: the solid-tumor option is closed, so every incremental research dollar and every remaining month of cash now has to buy a myelofibrosis label, not a second franchise.
The tension is capital, not science. Cash and investments sit near $65 million at mid-year against a $16 million principal payment due in September. Management states that making that payment without new money or a waiver drops liquidity below the $10 million covenant and constitutes an event of default. The share price near $2 already treats common as a thin residual. Enterprise claims from the term loan, converts, and the HealthCare Royalty obligation exceed $300 million. Market value near $41 million is the stub on top of those claims. The question the next several weeks resolve is not whether SENTRY is interesting. It is whether common holders still own the upside if the filing is accepted.